{"id":826822,"date":"2025-03-18T08:22:26","date_gmt":"2025-03-18T12:22:26","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/cidara-therapeutics-announces-two-presentations-on-cd388-in-influenza-at-international-conference-on-antiviral-research-icar-2025\/"},"modified":"2025-03-18T08:22:26","modified_gmt":"2025-03-18T12:22:26","slug":"cidara-therapeutics-announces-two-presentations-on-cd388-in-influenza-at-international-conference-on-antiviral-research-icar-2025","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/cidara-therapeutics-announces-two-presentations-on-cd388-in-influenza-at-international-conference-on-antiviral-research-icar-2025\/","title":{"rendered":"Cidara Therapeutics Announces Two Presentations on CD388 in Influenza\u00a0at International Conference on Antiviral Research (ICAR) 2025"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">SAN DIEGO, March  18, 2025  (GLOBE NEWSWIRE) &#8212; Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak<sup>\u00ae<\/sup>\u00a0platform to develop drug-Fc conjugate (DFC) immunotherapies, today announced two upcoming presentations at the 38<sup>th<\/sup> International Conference on Antiviral Research (ICAR). The conference takes place from March 17-21, 2025 in Las Vegas, Nevada. Cidara\u2019s presentations will highlight the study design, demographic information, and preliminary safety data from the ongoing Phase 2b NAVIGATE trial of CD388, as well as dose optimization models for evaluation of CD388 in a Phase 3 study.<\/p>\n<p>\n        <strong>Presentation details: <\/strong>\n      <\/p>\n<p>\n        <strong>Title: <\/strong>NAVIGATE: A Phase 2b, Randomized, Double-blind, Placebo-controlled, Multicenter Dose-ranging Study to Evaluate the Efficacy and Safety of CD388, a Novel Long-acting Antiviral Conjugate, for Prevention of Influenza in Subjects not at Risk for Influenza Complications<br \/><strong>Presenter: <\/strong>James Alexander<br \/><strong>Abstract number:<\/strong> 361 <br \/><strong>Date\/Time:<\/strong> Poster Session 1: Tuesday, March 18, 2025, 5:15-6:15pm PT; Poster Session 2: Thursday, March 20, 2025, 9-10am PT <br \/><strong>Summary: <\/strong>The Phase 2b NAVIGATE trial to evaluate the safety and preventative efficacy of CD388 in a real-world environment completed enrollment of more than 5,000 participants in the United States and the UK. Prior Phase 1 and Phase 2a clinical data have shown that CD388, administered by subcutaneous injection, appeared to be well-tolerated and efficacious in healthy human volunteer studies. The results of the Phase 2b trial will inform dose selection and design for the planned Phase 3 development program.<\/p>\n<p>\n        <strong>Title:<\/strong> Real World Data-Based Modeling of Seasonal Influenza Variations to Support Clinical Dose Selection of CD388, A Novel Antiviral in Development for Prevention of Seasonal and Pandemic Influenza <br \/><strong>Presenter:<\/strong> Shawn Flanagan<br \/><strong>Abstract number:<\/strong> 352 <br \/><strong>Date\/Time:<\/strong> Poster Session 1: Tuesday, March 18, 2025, 6:15-7:15pm PT; Poster Session 2: Thursday, March 20, 2025, 8-9am PT <br \/><strong>Summary: <\/strong>In trials involving community acquired infections, like influenza, variations in disease incidence over time may complicate interpretation of drug effect in Phase 2 and Phase 3 trials across multiple seasons, especially for long-acting drugs like CD388. Advanced model-based analysis was conducted to improve decision power based on simulated Phase 2 results over different flu seasons. While a standard proportions test was shown to be sensitive to influenza seasonal variations, the model-based analysis was not and increased decision power for clinical dose selection of CD388 for Phase 3.<\/p>\n<p>\n        <strong>About<\/strong>\u00a0<strong>CD388<\/strong><br \/>CD388 is an investigational drug-Fc conjugate (DFC) comprised of multiple copies of a potent small molecule neuraminidase inhibitor stably conjugated to a proprietary Fc fragment of a human antibody. DFCs are not vaccines or monoclonal antibodies but are low molecular weight biologics which are designed to function as long-acting small molecule inhibitors. CD388 was designed to provide universal protection against all known strains of seasonal and pandemic influenza with the potential to provide season-long protection with a single subcutaneous or intramuscular administration. Importantly, because CD388 is not a vaccine, its activity is not reliant on an immune response and thereby is expected to be efficacious in individuals regardless of immune status. More information can be found at:\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=6bGgSm33xlcxkaapWgJaosqh0GR14JnNJ1Vr_Sz6ixkQ5sYHkzjwr2TWjL4xU9KwezBIBtM2sWVfycZR2R8PiTqeDreLRZkk8YtQg6Vzzayx30Rr5he3slzV7Zs3iqeq1ZSayP1FYXz4MtzHWAp3rifBDi6ktz-KELXjwfe1cpAVJF5HJHAw7ne_h1pxydwFQXJSXitsdpeSTGJLwKoLvhIZO8FwX8LPwgWXANTs7mVCxjJtaJoilcxWxAcBGSD3rm9Hseh53ALZWBi5GgzZHqpaoEI4Csb6ERr2uX3rkpCKxnWRBh58hitBxGJeO_V3HTslBBW80nLG3qkMAdwsrkoZQXGo-hmL9yHOWrMGrCSOuc4XIfTA7N9-uDi-a0wsgBUM0wZSMwBVZQZxsTVtvozwAfmuBhAeGPcfkRnfoLydNY4Idge-rm6mwxE2tEBi1fp8gX6uA5RdIX8rAFM4ETuw15R9v2nOYFBJTboSwMCZp4DIqqhHfbb6YDAj5ywLBE_xYJoPf3w6q9V3_jVv4nGMaG3AmdhjeawCn0ooNgI8DqcARZE2nBnnWceHjjsZC3ZcQaJgFhWF9I-jf6WGVDdv6T_11VIL7BzBgJKNG3s5kRcqpyQJTv7SW5z2avnk\" rel=\"nofollow\" target=\"_blank\">https:\/\/www.cidara.com\/cloudbreak\/influenza\/<\/a>.<\/p>\n<p>\n        <strong>About Cidara Therapeutics<\/strong><br \/>\n        <br \/>Cidara Therapeutics is using its proprietary Cloudbreak<sup>\u00ae<\/sup>\u00a0platform to develop novel drug-Fc conjugates (DFCs) comprising targeted small molecules or peptides coupled to a proprietary human antibody fragment (Fc). Cidara\u2019s lead DFC candidate, CD388, is a long-acting antiviral designed to achieve universal prevention of seasonal and pandemic influenza with a single dose by directly inhibiting viral proliferation. In June 2023, CD388 was granted Fast Track Designation by the U.S. Food and Drug Administration (FDA), and the Company announced completion of enrollment of its Phase 2b NAVIGATE trial in December 2024. Additional DFCs have been developed for oncology and in July 2024 Cidara received IND clearance for CBO421 which is intended to target CD73 in solid tumors. Cidara is headquartered in San Diego, California. For more information, please visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=o2aD1MqHBImQDFUyYXXd2MDxsiJ-uBENjjDQ3R-bIj3PXCi2vxbLKpWCkEgl8ijpBpBVROcX1BowYyyUwlUHqA==\" rel=\"nofollow\" target=\"_blank\">www.cidara.com<\/a>.<\/p>\n<p>\n        <strong>Forward-Looking Statements<\/strong><br \/>\n        <br \/>This release contains \u201cforward-looking statements\u201d within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. \u201cForward-looking statements\u201d describe future expectations, plans, results, or strategies and are generally preceded by words such as \u201canticipates,\u201d \u201cexpect,\u201d \u201cintends,\u201d \u201cbelieves,\u201d \u201cmay,\u201d \u201cplan\u201d or \u201cwill\u201d. Forward-looking statements in this release include, but are not limited to, statements related to the potential of and future plans for CD388, and promising CD388 clinical data generated to date. Such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, such as unanticipated delays in or negative results from Cidara\u2019s clinical trials and other risks related to clinical development, delays in action by regulatory authorities, other obstacles on the enrollment of patients or other aspects of CD388 or other DFC development and other risks and uncertainties associated with Cidara\u2019s business in general. These and other risks are identified under the caption \u201cRisk Factors\u201d in Cidara\u2019s Annual Report on Form 10-K for the fiscal year ended December 31, 2024 and other filings subsequently made with the SEC. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management\u2019s assumptions and estimates as of such date. Cidara does not undertake any obligation to publicly update any forward-looking statements, whether as a result of the receipt of new information, the occurrence of future events or otherwise.<\/p>\n<p>\n        <strong>INVESTOR CONTACT:<\/strong><br \/>\n        <br \/>Brian Ritchie<br \/>LifeSci Advisors<br \/>(212) 915-2578<br \/>britchie@lifesciadvisors.com<\/p>\n<p>\n        <strong>MEDIA CONTACT:<\/strong><br \/>\n        <br \/>Michael Fitzhugh<br \/>LifeSci Communications<br \/>(628) 234-3889<br \/>mfitzhugh@lifescicomms.com<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM5NTk4NiM2ODEwNjUyIzUwMDExMDg1NQ==\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/ZDU0ZTg3MjAtYTNkMi00YmMyLThhYjYtNzdkZjRkY2YxNDBlLTUwMDExMDg1NS0yMDI1LTAzLTE4LWVu\/tiny\/Cidara-Therapeutics-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>SAN DIEGO, March 18, 2025 (GLOBE NEWSWIRE) &#8212; Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak\u00ae\u00a0platform to develop drug-Fc conjugate (DFC) immunotherapies, today announced two upcoming presentations at the 38th International Conference on Antiviral Research (ICAR). The conference takes place from March 17-21, 2025 in Las Vegas, Nevada. Cidara\u2019s presentations will highlight the study design, demographic information, and preliminary safety data from the ongoing Phase 2b NAVIGATE trial of CD388, as well as dose optimization models for evaluation of CD388 in a Phase 3 study. Presentation details: Title: NAVIGATE: A Phase 2b, Randomized, Double-blind, Placebo-controlled, Multicenter Dose-ranging Study to Evaluate the Efficacy and Safety of CD388, a Novel Long-acting Antiviral Conjugate, for Prevention of Influenza in &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/cidara-therapeutics-announces-two-presentations-on-cd388-in-influenza-at-international-conference-on-antiviral-research-icar-2025\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Cidara Therapeutics Announces Two Presentations on CD388 in Influenza\u00a0at International Conference on Antiviral Research (ICAR) 2025&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-826822","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Cidara Therapeutics Announces Two Presentations on CD388 in Influenza\u00a0at International Conference on Antiviral Research (ICAR) 2025 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/cidara-therapeutics-announces-two-presentations-on-cd388-in-influenza-at-international-conference-on-antiviral-research-icar-2025\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Cidara Therapeutics Announces Two Presentations on CD388 in Influenza\u00a0at International Conference on Antiviral Research (ICAR) 2025 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"SAN DIEGO, March 18, 2025 (GLOBE NEWSWIRE) &#8212; Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak\u00ae\u00a0platform to develop drug-Fc conjugate (DFC) immunotherapies, today announced two upcoming presentations at the 38th International Conference on Antiviral Research (ICAR). The conference takes place from March 17-21, 2025 in Las Vegas, Nevada. Cidara\u2019s presentations will highlight the study design, demographic information, and preliminary safety data from the ongoing Phase 2b NAVIGATE trial of CD388, as well as dose optimization models for evaluation of CD388 in a Phase 3 study. Presentation details: Title: NAVIGATE: A Phase 2b, Randomized, Double-blind, Placebo-controlled, Multicenter Dose-ranging Study to Evaluate the Efficacy and Safety of CD388, a Novel Long-acting Antiviral Conjugate, for Prevention of Influenza in &hellip; Continue reading &quot;Cidara Therapeutics Announces Two Presentations on CD388 in Influenza\u00a0at International Conference on Antiviral Research (ICAR) 2025&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/cidara-therapeutics-announces-two-presentations-on-cd388-in-influenza-at-international-conference-on-antiviral-research-icar-2025\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-03-18T12:22:26+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM5NTk4NiM2ODEwNjUyIzUwMDExMDg1NQ==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cidara-therapeutics-announces-two-presentations-on-cd388-in-influenza-at-international-conference-on-antiviral-research-icar-2025\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cidara-therapeutics-announces-two-presentations-on-cd388-in-influenza-at-international-conference-on-antiviral-research-icar-2025\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Cidara Therapeutics Announces Two Presentations on CD388 in Influenza\u00a0at International Conference on Antiviral Research (ICAR) 2025\",\"datePublished\":\"2025-03-18T12:22:26+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cidara-therapeutics-announces-two-presentations-on-cd388-in-influenza-at-international-conference-on-antiviral-research-icar-2025\\\/\"},\"wordCount\":930,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cidara-therapeutics-announces-two-presentations-on-cd388-in-influenza-at-international-conference-on-antiviral-research-icar-2025\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM5NTk4NiM2ODEwNjUyIzUwMDExMDg1NQ==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cidara-therapeutics-announces-two-presentations-on-cd388-in-influenza-at-international-conference-on-antiviral-research-icar-2025\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cidara-therapeutics-announces-two-presentations-on-cd388-in-influenza-at-international-conference-on-antiviral-research-icar-2025\\\/\",\"name\":\"Cidara Therapeutics Announces Two Presentations on CD388 in Influenza\u00a0at International Conference on Antiviral Research (ICAR) 2025 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cidara-therapeutics-announces-two-presentations-on-cd388-in-influenza-at-international-conference-on-antiviral-research-icar-2025\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cidara-therapeutics-announces-two-presentations-on-cd388-in-influenza-at-international-conference-on-antiviral-research-icar-2025\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM5NTk4NiM2ODEwNjUyIzUwMDExMDg1NQ==\",\"datePublished\":\"2025-03-18T12:22:26+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cidara-therapeutics-announces-two-presentations-on-cd388-in-influenza-at-international-conference-on-antiviral-research-icar-2025\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cidara-therapeutics-announces-two-presentations-on-cd388-in-influenza-at-international-conference-on-antiviral-research-icar-2025\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cidara-therapeutics-announces-two-presentations-on-cd388-in-influenza-at-international-conference-on-antiviral-research-icar-2025\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM5NTk4NiM2ODEwNjUyIzUwMDExMDg1NQ==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM5NTk4NiM2ODEwNjUyIzUwMDExMDg1NQ==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cidara-therapeutics-announces-two-presentations-on-cd388-in-influenza-at-international-conference-on-antiviral-research-icar-2025\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Cidara Therapeutics Announces Two Presentations on CD388 in Influenza\u00a0at International Conference on Antiviral Research (ICAR) 2025\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Cidara Therapeutics Announces Two Presentations on CD388 in Influenza\u00a0at International Conference on Antiviral Research (ICAR) 2025 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/cidara-therapeutics-announces-two-presentations-on-cd388-in-influenza-at-international-conference-on-antiviral-research-icar-2025\/","og_locale":"en_US","og_type":"article","og_title":"Cidara Therapeutics Announces Two Presentations on CD388 in Influenza\u00a0at International Conference on Antiviral Research (ICAR) 2025 - Market Newsdesk","og_description":"SAN DIEGO, March 18, 2025 (GLOBE NEWSWIRE) &#8212; Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak\u00ae\u00a0platform to develop drug-Fc conjugate (DFC) immunotherapies, today announced two upcoming presentations at the 38th International Conference on Antiviral Research (ICAR). The conference takes place from March 17-21, 2025 in Las Vegas, Nevada. Cidara\u2019s presentations will highlight the study design, demographic information, and preliminary safety data from the ongoing Phase 2b NAVIGATE trial of CD388, as well as dose optimization models for evaluation of CD388 in a Phase 3 study. Presentation details: Title: NAVIGATE: A Phase 2b, Randomized, Double-blind, Placebo-controlled, Multicenter Dose-ranging Study to Evaluate the Efficacy and Safety of CD388, a Novel Long-acting Antiviral Conjugate, for Prevention of Influenza in &hellip; Continue reading \"Cidara Therapeutics Announces Two Presentations on CD388 in Influenza\u00a0at International Conference on Antiviral Research (ICAR) 2025\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/cidara-therapeutics-announces-two-presentations-on-cd388-in-influenza-at-international-conference-on-antiviral-research-icar-2025\/","og_site_name":"Market Newsdesk","article_published_time":"2025-03-18T12:22:26+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM5NTk4NiM2ODEwNjUyIzUwMDExMDg1NQ==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cidara-therapeutics-announces-two-presentations-on-cd388-in-influenza-at-international-conference-on-antiviral-research-icar-2025\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cidara-therapeutics-announces-two-presentations-on-cd388-in-influenza-at-international-conference-on-antiviral-research-icar-2025\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Cidara Therapeutics Announces Two Presentations on CD388 in Influenza\u00a0at International Conference on Antiviral Research (ICAR) 2025","datePublished":"2025-03-18T12:22:26+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cidara-therapeutics-announces-two-presentations-on-cd388-in-influenza-at-international-conference-on-antiviral-research-icar-2025\/"},"wordCount":930,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cidara-therapeutics-announces-two-presentations-on-cd388-in-influenza-at-international-conference-on-antiviral-research-icar-2025\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM5NTk4NiM2ODEwNjUyIzUwMDExMDg1NQ==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cidara-therapeutics-announces-two-presentations-on-cd388-in-influenza-at-international-conference-on-antiviral-research-icar-2025\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/cidara-therapeutics-announces-two-presentations-on-cd388-in-influenza-at-international-conference-on-antiviral-research-icar-2025\/","name":"Cidara Therapeutics Announces Two Presentations on CD388 in Influenza\u00a0at International Conference on Antiviral Research (ICAR) 2025 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cidara-therapeutics-announces-two-presentations-on-cd388-in-influenza-at-international-conference-on-antiviral-research-icar-2025\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cidara-therapeutics-announces-two-presentations-on-cd388-in-influenza-at-international-conference-on-antiviral-research-icar-2025\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM5NTk4NiM2ODEwNjUyIzUwMDExMDg1NQ==","datePublished":"2025-03-18T12:22:26+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cidara-therapeutics-announces-two-presentations-on-cd388-in-influenza-at-international-conference-on-antiviral-research-icar-2025\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/cidara-therapeutics-announces-two-presentations-on-cd388-in-influenza-at-international-conference-on-antiviral-research-icar-2025\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cidara-therapeutics-announces-two-presentations-on-cd388-in-influenza-at-international-conference-on-antiviral-research-icar-2025\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM5NTk4NiM2ODEwNjUyIzUwMDExMDg1NQ==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM5NTk4NiM2ODEwNjUyIzUwMDExMDg1NQ=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cidara-therapeutics-announces-two-presentations-on-cd388-in-influenza-at-international-conference-on-antiviral-research-icar-2025\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Cidara Therapeutics Announces Two Presentations on CD388 in Influenza\u00a0at International Conference on Antiviral Research (ICAR) 2025"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/826822","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=826822"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/826822\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=826822"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=826822"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=826822"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}